Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial. - Archive ouverte HAL Access content directly
Journal Articles European Heart Journal Year : 2011

Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial.

(1, 2) , (3) , (4) , (5) , (6, 7) , (8) , (3, 5) , (9) , (10) , (4) , (1, 2) , (5) , (6, 7) , (11) , (3) , (10) , (12) , (1, 2) , (13) , (4) , (2) , (5) , (14) , (15) , (16) , (17) , (5) , (8) , (3) , (5)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
Alain Manrique
  • Function : Author
Sophie Susen
Guillaume Lamirault
Jean-Michel Nguyen
  • Function : Author

Abstract

AIMS: Intracoronary administration of autologous bone marrow cells (BMCs) leads to a modest improvement in cardiac function, but the effect on myocardial viability is unknown. The aim of this randomized multicentre study was to evaluate the effect of BMC therapy on myocardial viability in patients with decreased left ventricular ejection fraction (LVEF) after acute myocardial infarction (AMI) and to identify predictive factors for improvement of myocardial viability. METHODS AND RESULTS: One hundred and one patients with AMI and successful reperfusion, LVEF ≤45%, and decreased myocardial viability (resting Tl201-SPECT) were randomized to either a control group (n = 49) or a BMC group (n = 52). Primary endpoint was improvement of myocardial viability 3 months after AMI. Baseline mean LVEF measured by radionuclide angiography was 36.3 ± 6.9%. Bone marrow cell infusion was performed 9.3 ± 1.7 days after AMI. Myocardial viability improved in 16/47 (34%) patients in the BMC group compared with 7/43 (16%) in the control group (P = 0.06). The number of non-viable segments becoming viable was 0.8 ± 1.1 in the control group and 1.2 ± 1.5 in the BMC group (P = 0.13). Multivariate analysis including major post-AMI prognostic factors showed a significant improvement of myocardial viability in BMC vs. control group (P = 0.03). Moreover, a significant adverse role for active smoking (P = 0.04) and a positive trend for microvascular obstruction (P = 0.07) were observed. CONCLUSION: Intracoronary autologous BMC administration to patients with decreased LVEF after AMI was associated with improvement of myocardial viability in multivariate-but not in univariate-analysis. A large multicentre international trial is warranted to further document the efficacy of cardiac cell therapy and better define a group of patients that will benefit from this therapy. Clinical Trial Registration Information: URL: http://www.clinicaltrials.gov. Unique identifier NCT00200707.
Fichier principal
Vignette du fichier
inserm-00543644_edited.pdf (453.97 Ko) Télécharger le fichier
Vignette du fichier
Additional_data.pdf (134.22 Ko) Télécharger le fichier
Vignette du fichier
FINAL_REVISION_3_3_with_figures.pdf (672.24 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Format : Other
Origin : Files produced by the author(s)
Loading...

Dates and versions

inserm-00543644 , version 1 (06-12-2010)

Identifiers

Cite

Jérôme Roncalli, Frédéric Mouquet, Christophe Piot, Jean-Noel Trochu, Philippe Le Corvoisier, et al.. Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial.. European Heart Journal, 2011, 32 (14), pp.1748-57. ⟨10.1093/eurheartj/ehq455⟩. ⟨inserm-00543644⟩
552 View
1178 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More